Despite recent advances in both diagnosis and prevention, the incidence of invasive fungal
infections continues to rise. Available antifungal agents to treat invasive fungal infections …

Increasing incidence of invasive fungal infections combined with a growing population of
immunocompromised hosts has created a rising need for antifungal agents. Isavuconazole …

Objective: To review the pharmacology, chemistry, in vitro susceptibility, pharmacokinetics,
clinical efficacy, safety, tolerability, dosage, and administration of isavuconazole, a triazole …

Isavuconazole is the newest of the clinically available advanced generation triazole
antifungals and is active against a variety of yeasts, molds, and dimorphic fungi. Its current …

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality.
Isavuconazole (BAL4815) is a promising novel broad-spectrum triazole in late-stage clinical …

Isavuconazole is a second-generation triazole with activity against a broad spectrum of
clinically important fungi. Its water-soluble prodrug, isavuconazonium sulfate (Cresemba®) …

Introduction: Invasive fungal infections remain a leading cause of infectious morbidity and
mortality in immunocompromised patients. There are relatively few effective antifungal …

Coinciding with the continually increasing population of immunocompromised patients
worldwide, the incidence of invasive fungal infections has grown over the past 4 decades …

Objective To review the place in therapy of isavuconazole, the active metabolite of
isavuconazonium sulfate, via a review of the available literature on drug chemistry, spectrum …

Isavuconazole (ISA) is a triazole antifungal agent recommended for treatment of invasive
aspergillosis or mucormycosis. The objective of this study was to evaluate ISA levels in a …